GlassScriptPhysician profile
David J Drewitz
NPI 1174574610
$4,861.17
in general payments reported to CMS, 2019-2025
32 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $163 · 2021: $772 · 2022: $760 · 2023: $870 · 2024: $907 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,816 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,816.25 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,565.45 | 2019-2025 | Rinvoq, Linzess, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $551.70 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $393.70 | 2019-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $367.62 | 2022-2025 | |
| Janssen Biotech, INC. | $269.07 | 2019-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $255.25 | 2019-2025 | |
| Pfizer INC. | $229.75 | 2019-2025 | |
| Celgene Corporation | $138.11 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $115.53 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $106.64 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $100.66 | 2024-2025 | Voquezna |
| Fujifilm Healthcare Americas Corporation | $85.98 | 2024 | Fujifilm |
| Ardelyx, INC. | $82.46 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $76.04 | 2021-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $75.40 | 2023-2025 | Dupixent |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $52.20 | 2022-2025 | Rebyota |
| Merck Sharp & Dohme LLC | $51.85 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $48.48 | 2021 | |
| Redhill Biopharma INC. | $44.74 | 2021-2022 | |
| Napo Pharmaceuticals INC | $36.41 | 2025 | Mytesi |
| Abbott Laboratories | $27.07 | 2024 | Proclaim |
| Davol INC. | $24.09 | 2024 | Phasix Mesh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.93 | 2023 | Cyltezo |
| Amgen INC. | $22.28 | 2021 | |
| Novo Nordisk INC | $20.86 | 2025 | Wegovy |
| Boston Scientific Corporation | $19.11 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.76 | 2022 | |
| Braintree Laboratories, INC. | $16.40 | 2021 | |
| Lucid Diagnostics INC. | $14.96 | 2022 | |
| Intra-Sana Laboratories | $14.01 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Evoke Pharma, INC. | $13.66 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Drewitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.